There is new hope for people who have HER2 type of breast cancer – a type of breast cancer that is infamous for its relapse rate. HER2 also affects 20-30% of breast cancer cases. A new drug, Herception, has reduced relapse by 50%!

“The results of these clinical trials provided consistent evidence that treatment with Herceptin following standard chemotherapy reduces the risk of cancer recurrence by about 50%. Herceptin has clearly demonstrated that it provides the best chance of long-term survival when used as early as possible in the course of the disease.”